Literature DB >> 17613416

Radium-223 for men with hormone-refractory prostate cancer and bone metastases.

Mike D Shelley, Malcolm D Mason.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17613416     DOI: 10.1016/S1470-2045(07)70180-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  6 in total

Review 1.  Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer.

Authors:  Christopher J Logothetis; Gary E Gallick; Sankar N Maity; Jeri Kim; Ana Aparicio; Eleni Efstathiou; Sue-Hwa Lin
Journal:  Cancer Discov       Date:  2013-06-28       Impact factor: 39.397

2.  Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.

Authors:  Jorge A Carrasquillo; Joseph A O'Donoghue; Neeta Pandit-Taskar; John L Humm; Dana E Rathkopf; Susan F Slovin; Matthew J Williamson; Kristine Lacuna; Anne-Kirsti Aksnes; Steven M Larson; Howard I Scher; Michael J Morris
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-08       Impact factor: 9.236

Review 3.  The biology of the sodium iodide symporter and its potential for targeted gene delivery.

Authors:  Mohan Hingorani; Christine Spitzweg; Georges Vassaux; Kate Newbold; Alan Melcher; Hardev Pandha; Richard Vile; Kevin Harrington
Journal:  Curr Cancer Drug Targets       Date:  2010-03       Impact factor: 3.428

Review 4.  The Na+/I- symporter (NIS): mechanism and medical impact.

Authors:  Carla Portulano; Monika Paroder-Belenitsky; Nancy Carrasco
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

Review 5.  Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.

Authors:  Tania Stafinski; Christopher J McCabe; Devidas Menon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

6.  [Pain palliation using unsealed radionuclides].

Authors:  W U Kampen; M Fischer
Journal:  Schmerz       Date:  2008-12       Impact factor: 1.107

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.